Seneca Biopharma, Inc. (SNCA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNCA Stock Price Chart Interactive Chart >
SNCA Price/Volume Stats
|Current price||$9.96||52-week high||$10.03|
|Prev. close||$1.68||52-week low||$0.50|
|Day high||$10.03||Avg. volume||3,775,260|
|50-day MA||$1.58||Dividend yield||N/A|
|200-day MA||$1.02||Market Cap||172.27M|
Seneca Biopharma, Inc. (SNCA) Company Bio
Seneca Biopharma, Inc. operates as a biopharmaceutical company. The Company develops novel treatments for diseases of unmet medical need. Seneca Biopharma serves customers in the State of Maryland.
Most Popular Stories View All
SNCA Latest News Stream
|Loading, please wait...|
SNCA Latest Social Stream
View Full SNCA Social Stream
Latest SNCA News From Around the Web
Below are the latest news stories about Seneca Biopharma Inc that investors may wish to consider to help them evaluate SNCA as an investment opportunity.
Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), disclosed on April 23, 2021, the passing of the final proposal required for approval of the proposed merger between Seneca and Leading Biosciences, Inc. ("LBS"). The Merger is expected to close on or about April 27, 2021 and the new combined company, Palisades Bio, is expected to begin trading on the Nasdaq Capital Market on or about April 28, 2021 under the ticker "PALI".
Thursday's here and we're taking a look at the biggest pre-market movers investors will want to know about before the opening bell.
Leading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label Study
CARLSBAD, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS” or "the Company"), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (Nasdaq: SNCA), subject to certain conditions to be completed, to form Palisade Bio, Inc., announced data from an open label GI surgery study with lead asset LB1148 that provided an early indication of efficacy signal in reducing post-surgical adhesions following elective bowel resection. No abdominal adhesions were observed at the time of a follow-up surgery in two patients treated with LB1148. Although these are early data in a limited number of patients, the data may support the Company's ongoing Phase 2 clinical trial to evaluate the impact of LB1148 on retu...
Leading BioSciences Releases Video Message Encouraging Seneca Biopharma, Inc. Stockholders to Vote at the Virtual Special Meeting on April 23, 2021
Video messages urges Seneca stockholders to vote in support of Proposal #1, the reverse stock split, in order to approve the proposed transaction. Proposal 1 was favored by a wide margin by Seneca stockholders who voted at the virtual Special Meeting on April 9, 2021. CARLSBAD, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal complications, today released a video message from its CEO, Dr. Tom Hallam, to address the status of the proposed merger transaction with Seneca Biopharma, Inc. (Nasdaq: SNCA) (“Seneca”). All proposals, with the exception of Proposal #1, the reverse stock split (the “Reverse Split Proposal”), have been approved by Seneca stockholders. The Reverse S...
Seneca Biopharma, Inc. Announces (i) Voting Results from the Special Meeting of Stockholders and (ii) New Special Meeting Date of April 23, 2021
Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), announced the preliminary voting results of its Special Meeting of Stockholders on April 9, 2021. At the Special Meeting, Seneca asked stockholders to approve six proposals related to its proposed merger transaction with Leading BioSciences, Inc. ("LBS"), a biopharma company advancing therapies for acute and chronic gastrointestinal complications. All proposals, with the exception of proposal #1 for a reverse stock split (the "Reverse Split Proposal"), were approved by Seneca stockholders. In order to solicit additional votes for the Reverse Split Proposal, the Special Meeting was adjourned only with respect to the Reverse Split Proposal until April 23, 2021 at 11:00 AM ET and will be held virtually at www.virtualshareho...
SNCA Price Returns